Skip to main content
. 2022 Mar 21;18(3):187–197. doi: 10.1007/s13181-021-00873-0

Table 1.

Study design scheme by dosing sequence.

Dosing sequence Expected number of evaluable subjects (N) Period 1
(visit 1; day 1)
Period 2
(visit 2; day 8)
Period 3
(visit 3; day 15)
A 4 Low-dose sublingual High-dose sublingual IV
B 4 High-dose sublingual IV Low-dose sublingual
C 4 IV Low-dose sublingual High-dose sublingual

IV, intravenous atropine sulfate 1.0 mg (0.4 mg/mL) administered via IV route

Low-dose sublingual = 0.5 mg (50 µL) of atropine sulfate 1% ophthalmic solution, administered via sublingual route

High-dose sublingual = 1.0 mg (100 µL) of atropine sulfate 1% ophthalmic solution, administered via sublingual route